Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers

With significant upside potential, Bristol-Myers Squibb Company (NYSE:BMY) secures a spot on our list of the 20 NYSE Stocks with the Lowest P/E Ratios.

Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers

Bristol-Myers Squibb Company (NYSE:BMY) announced on September 25, 2025, that it would begin selling its psoriasis medication Sotyktu directly to cash-paying U.S. customers at a price more than 80% lower than its list price, reducing monthly costs from $6,828 to around $950. Targeting uninsured and underinsured patients, the program launched in January via the new BMS Patient Connect platform, bypassing traditional pharmacy benefit managers and insurers.

This move followed the Trump administration’s “most-favored-nation” policy, which increased pressure on pharmaceutical companies to align U.S. drug prices with those abroad. Bristol-Myers Squibb Company (NYSE:BMY) also announced on September 22, 2025, that it would introduce a new medication for schizophrenia.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and marketing of therapies across oncology, hematology, immunology, cardiovascular disease, neuroscience, and other therapeutic areas. It is one of the Stocks with Low PE Ratio.

While we acknowledge the potential of BMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.